Some of my most satisfying moments as a clinician over the past 50 years have been when I conducted in vivo behavior therapy exposure and practice with patients suffering from anxiety and phobias.

What if CAR T cells, revolutionary cancer fighters normally manufactured in the lab, could be created inside the patient? This quest to simplify CAR T therapy has brought two biotech companies to a ...

In vivo CAR T-cell therapy could revolutionize cancer treatment by bypassing traditional manufacturing, reducing costs, and minimizing adverse events. Kelonia Therapeutics' KLN-1010 has shown ...

Gilead is soaring to new heights in the CAR-T therapeutics sector, acquiring in vivo cell therapy specialist Interius BioTherapeutics via its subsidiary Kite for $350m. The deal will integrate ...

Cell therapy’s next breakthrough could be the engineering of these cells inside the patient. Two deals more than four years apart put Astellas Pharma in position to ramp up its work developing these ...

Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first candidates in its in vivo pipeline. CRSP’s Positive In Vivo Therapy Data Last ...

Authors explore complexities in scaling gene-therapy production with special attention is to monitoring and enhancing ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and signing a $238 million biobucks pact at the same time as it searches for a ...

Rocket Pharmaceuticals stock trades at ~$19.5 today - back in December 2021 it had hit highs of >$60. The highs were achieved when Rocket's in vivo gene therapy showed promise treating patients with a ...

When Bruce Levine and his colleagues began attempting to engineer immune cells to fight cancer in the 1990s, few people thought they would succeed. “The wider community was very sceptical,” says ...